ALXN News and Press, Alexion Pharmaceuticals Inc. From 09/09/19

- Eidos grants Alexion exclusive license to develop and commercialize AG10 in Japan - - Phase 3 study of AG10 in ATTR cardiomyopathy underway in U.S. & Europe; Phase 3 trial in ATTR polyneuropathy planned to initiate in second half of 2019 - - Agreement expands Alexion’...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Noteworthy events during the week of September 8 - 14 for healthcare investors. More news on: Alnylam Pharmaceuticals, Inc., Johnson & Johnson, Xeris Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...

The European Patent Office has rejected two patent applications from Alexion Pharmaceuticals (NASDAQ: ALXN ) for pharmaceutical compositions and composition of matter of top seller Soliris (eculizumab), potentially opening the European market to biosimilars as early as 2023 according to Le...

Shares of Alexion Pharmaceuticals (NASDAQ: ALXN) ended August down 11% according to data provided by S&P Global Market Intelligence , as the biotech experienced a roller coaster to finish off the month. Interestingly, both the highs and lows involved Amgen (NASDAQ: AMGN) . Image so...

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the 17th Annual Morgan Stanley Global Healthcare Conference in New York, NY on Monday, September 9th, 2019 at 8:45 a.m. ET. An audio webcast of the presentation will be available live. You can access the...

Friday was a relatively quiet day on Wall Street, with major indexes staying relatively close to where they began the session. Investors are getting conflicting readings on the prospects for economic growth going forward, with some signs pointing to continued strength while others call for cauti...

Alexion Pharmaceuticals (NASDAQ: ALXN ) is down  8%  premarket on modest volume in reaction to Amgen's (NASDAQ: AMGN ) challenge of three patents covering top seller Soliris (eculizumab). More news on: Alexion Pharmaceuticals, Inc., Amgen Inc., Healthcare stocks news, Stocks on t...

Ulta Beauty (NASDAQ: ULTA )  -25%  on Q2 earnings . More news on: Ulta Beauty, Inc., American Outdoor Brands Corporation, Alexion Pharmaceuticals, Inc., Stocks on the move, Read more ...